PER2 and neoplasm: Compared with the PER2 overexpression group, we observed an increased phenotype in the tumor weight of subcutaneous xenografts formed by oxaliplatin‐treated OSCC cells overexpressing both PER2 and PCNA (Figure 5j–m, Supporting Information).